101. [Decreased bone mineral density in HIV-infected children receiving highly active antiretroviral therapy].
- Author
-
Rojo Conejo P, Ramos Amador JT, García Piñar L, Ruano Fajardo C, Sánchez Granados JM, González Tomé MI, and Ruiz Contreras J
- Subjects
- Child, Child, Preschool, Cross-Sectional Studies, Female, Humans, Male, Surveys and Questionnaires, Antiretroviral Therapy, Highly Active adverse effects, Bone Density drug effects, HIV Infections drug therapy
- Abstract
Background: In developed countries, the introduction of highly active antiretroviral therapy (HAART) has greatly improved survival and quality of life in HIV-infected children. Nevertheless, worrisome metabolic and bone alterations are beginning to be observed., Objective: To evaluate the prevalence of alterations in bone mineral density and possible associated factors in a cohort of HIV-infected children receiving HAART., Patients and Methods: Bone dual energy X-ray absorptiometry (DEXA) was performed in 50 HIV-infected children in a tertiary hospital in Madrid after a median length of HAART of 54 months. Subsequently, the group with bone mineral loss was compared with the group without bone mineral loss., Results: Forty percent of the children studied had decreased bone mineral density, of which 36 % had osteopenia (18/50) and 4 % had osteoporosis (2/50). No statistically significant differences were found between the two groups in any of the factors analyzed., Conclusions: The prevalence of decreased bone mineral density in our cohort of HIV-infected children receiving HAART is high. The etiology and factors associated with this alteration are still not well known.
- Published
- 2004
- Full Text
- View/download PDF